Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

Sponsor
Hebei Medical University Fourth Hospital
Study ID
NCT05525767
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.

Study Details

This is an prospective, multicenter, single-arm clinical study.

Key Dates

First listed
Sep 2, 2022
Start date
Mar 31, 2022
Status verified
Aug 2025
Primary completion
Oct 31, 2026
Completion
Dec 31, 2028

Study Design

Enrollment
75 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Assigned Interventions
    Bevacizumab 10mg/Kg d1, 1/21d

Primary Outcome Measure

PCR [ Time Frame: 24 months ]

Central Contacts

Related Studies